OSU K12 Training Grant for Clinical Faculty Investigators

描述（由申请人提供）：本提案的目标是指导和有效培训基础科学和/或临床导向的转化研究方法的教员级研究人员。K12奖的实施将为血液肿瘤学、内科肿瘤学、放射肿瘤学和外科肿瘤学领域的基础转化科学家（博士、副博士和医学博士）和临床转化科学家（医学博士和医学博士/博士）的职业发展提供保障，确保有一批训练有素的人才致力于药物开发、癌症预防、控制和生存研究。俄亥俄州立大学综合癌症中心（OSUCCC）的K12更新继续其培训重点是早期药物开发以及更大的II/III期试验，但现在也扩展到基于先前批评的癌症预防，控制和生存研究。如建议，重点招募对普通实体瘤感兴趣的学者。OSUCCC显然致力于研究教育，并为有前途的初级教师提供优秀的培训和指导机会。俄勒冈州立大学血液学、内科肿瘤学、放射肿瘤学和外科肿瘤学部门都有强大的奖学金培训计划，不断招募新的初级教师，以促进我们癌症项目的扩展。也会从其他奖学金培训项目中招聘人员，特别注重对妇女、少数民族和不同种族背景的人进行甄别，以增加多样性。这个K12资助填补了一个重要的需求，通过扩展研究教育，培训和指导对发展专注于临床研究的学术生涯感兴趣的初级教师。此外，这将是OSUCCC唯一一个专门针对教师水平癌症职业发展的培训项目，因此与俄勒冈州立大学T32培训资助的任何研究员都没有重叠。这一策略将确保培训的连续性，并为个人提供成为独立临床研究者的能力。基于OSUCCC的整体实力和方向，正如其最近的同行评议得分为12分（例外），OSUCCC对K12的财政支持，不同部门和部门的财政支持，以及俄勒冈州立大学可用资源的广度所表明的那样，这个K12提案主要寻求培养两种类型的助理教授。第一组包括医学博士或博士教师（基础转化培训生），他们受过出色的基础科学训练，并希望从事与实验治疗学应用研究以及癌症预防、控制和生存相关的实验室研究。第二类包括医学博士或医学博士/博士教师（临床转化培训生），他们以临床为重点从事与患者相关的研究

DESCRIPTION (provided by applicant): The goal of this proposal is to mentor and effectively train faculty-level investigators in basic science and/or clinically-oriented approaches to translational research. Implementation of this K12 award for the career development of basic translational scientists (PhD, DVM, and MD) and clinical translational scientists (MD and MD/PhD) in Hematologic Oncology, Medical Oncology, Radiation Oncology and Surgical Oncology will ensure a cadre of highly-trained individuals dedicated to drug development as well as cancer prevention, control, and survivorship research. This K12 renewal from The Ohio State University Comprehensive Cancer Center (OSUCCC) continues its training focus on early drug development along with larger phase II/III trials, but now also extends to cancer prevention, control and survivorship research based on the previous critique. Focus on recruitment of scholars with interest in common solid tumors is also emphasized, as suggested. The OSUCCC is clearly dedicated to research education and providing outstanding training and mentoring opportunities to promising junior faculty. The OSU Divisions of Hematology, Medical Oncology, Radiation Oncology, and Surgical Oncology each have robust fellowship training programs that are continuously recruiting new junior faculty to facilitate expansion of our cancer program. Recruitment from other fellowship training programs also occurs, with particular focus on identification of women, minorities and people of different ethnic backgrounds to increase diversity. This K12 grant fills an important need by extending research education, training and mentoring to junior faculty interested in developing academic careers focused on clinical research. Moreover, it will be the only OSUCCC training program solely dedicated to career development in cancer at the faculty level, and therefore has no overlap with any of the OSU T32 training grants focused on fellows. This strategy will ensure continuity in training and provide individuals with the ability to become independent clinical investigators. Based upon the overall strength and direction of the OSUCCC, as demonstrated by its recent peer review score of 12 (exceptional), financial support of this K12 by OSUCCC, financial support by different Divisions and Departments, and breadth of resources available at OSU, this K12 proposal seeks to train primarily two types of assistant professors. The first group includes MD or PhD faculty (basic translational trainees) who have outstanding basic science training and desire to pursue laboratory investigation related to applied research in experimental therapeutics as well as cancer prevention, control, and survivorship. The second group includes MD or MD/PhD faculty (clinical translational trainees) who pursue patient-related research in clinically-focused experimental therapeutics and cancer prevention, control, or survivorship. Training plans tailored to each of these individual trainees will facilitate their success, with inclusion of a roust evaluation program to assess the success of the K12. This is best demonstrated by all of the current and past K12 scholars remaining in academic medicine and moving forward as independent clinical investigators.